Author:
Wang Feifei,Yasuhara Takao,Shingo Tetsuro,Kameda Masahiro,Tajiri Naoki,Yuan Wen Ji,Kondo Akihiko,Kadota Tomohito,Baba Tanefumi,Tayra Judith Thomas,Kikuchi Yoichiro,Miyoshi Yasuyuki,Date Isao
Abstract
Abstract
Background
Mesenchymal stem cells (MSCs) are pluripotent stem cells derived from bone marrow with secretory functions of various neurotrophic factors. Stromal cell-derived factor-1α (SDF-1α) is also reported as one of chemokines released from MSCs. In this research, the therapeutic effects of MSCs through SDF-1α were explored. 6-hydroxydopamine (6-OHDA, 20 μg) was injected into the right striatum of female SD rats with subsequent administration of GFP-labeled MSCs, fibroblasts, (i.v., 1 × 107 cells, respectively) or PBS at 2 hours after 6-OHDA injection. All rats were evaluated behaviorally with cylinder test and amphetamine-induced rotation test for 1 month with consequent euthanasia for immunohistochemical evaluations. Additionally, to explore the underlying mechanisms, neuroprotective effects of SDF-1α were explored using 6-OHDA-exposed PC12 cells by using dopamine (DA) assay and TdT-mediated dUTP-biotin nick-end labeling (TUNEL) staining.
Results
Rats receiving MSC transplantation significantly ameliorated behaviorally both in cylinder test and amphetamine-induced rotation test compared with the control groups. Correspondingly, rats with MSCs displayed significant preservation in the density of tyrosine hydroxylase (TH)-positive fibers in the striatum and the number of TH-positive neurons in the substantia nigra pars compacta (SNc) compared to that of control rats. In the in vitro study, SDF-1α treatment increased DA release and suppressed cell death induced by 6-OHDA administration compared with the control groups.
Conclusions
Consequently, MSC transplantation might exert neuroprotection on 6-OHDA-exposed dopaminergic neurons at least partly through anti-apoptotic effects of SDF-1α. The results demonstrate the potentials of intravenous MSC administration for clinical applications, although further explorations are required.
Publisher
Springer Science and Business Media LLC
Subject
Cellular and Molecular Neuroscience,General Neuroscience
Reference41 articles.
1. Hornykiewicz O: Parkinson's disease: from brain homogenate to treatment. Fed Proc. 1973, 32 (2): 183-90.
2. Treciokas LJ, Ansel RD, Markham CH: One to two year treatment of Parkinson's disease with levodopa. Calif Med. 1971, 114 (5): 7-14.
3. Péchadre JC, Larochelle L, Poirier LJ: Parkinsonian akinesia, rigidity and tremor in the monkey. Histopathological and neuropharmacological study. J Neurol Sci. 1976, 28 (2): 147-57. 10.1016/0022-510X(76)90100-3.
4. Yahr MD, Duvoisin RC, Hoehn MM, Schear MJ, Barrett RE: L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism. Am Neurol Assoc. 1968, 93: 56-63.
5. Cotzias GC: L-Dopa for Parkinsonism. N Engl J Med. 1968, 278 (11): 630.
Cited by
131 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献